Perspectives in melanoma: Meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)

Paolo A. Ascierto, Sanjiv S. Agarwala, Gerardo Botti, Alfredo Budillon, Michael A. Davies, Reinhard Dummer, Marc Ernstoff, Soldano Ferrone, Silvia Formenti, Thomas F. Gajewski, Claus Garbe, Omid Hamid, Roger S. Lo, Jason J. Luke, Oliver Michielin, Giuseppe Palmieri, Laurence Zitvogel, Francesco M. Marincola, Giuseppe Masucci, Corrado CaracòMagdalena Thurin, Igor Puzanov

Research output: Contribution to journalArticlepeer-review


Diagnosis of melanocytic lesions, correct prognostication of patients, selection of appropriate adjuvant and systemic therapies, and prediction of response to a given therapy remain very real challenges in melanoma. Recent studies have shown that immune checkpoint blockade that represents a forefront in cancer therapy, provide responses but they are not universal. Improved understanding of the tumor microenvironment, tumor immunity and response to therapy has prompted extensive translational and clinical research in melanoma. Development of novel biomarker platforms may help to improve diagnostics and predictive accuracy for selection of patients for specific treatment. There is a growing evidence that genomic and immune features of pre-treatment tumor biopsies may correlate with response in patients with melanoma and other cancers they have yet to be fully characterized and implemented clinically. For example, advancements in sequencing and the understanding of the tumor microenvironment in melanoma have led to the use of genome sequencing and gene expression for development of multi-marker assays that show association with inflammatory state of the tumor and potential to predict response to immunotherapy. As such, melanoma serves as a model system for understanding cancer immunity and patient response to immunotherapy, either alone or in combination with other treatment modalities. Overall, the aim for the translational and clinical studies is to achieve incremental improvements through the development and identification of optimal treatment regimens, which increasingly involve doublet as well as triplet combinations, as well as through development of biomarkers to improve immune response. These and other topics in the management of melanoma were the focus of discussions at the fourth Melanoma Bridge meeting (November 29th-December 1st, 2018, Naples, Italy), which is summarised in this report.

Original languageEnglish
Article number234
JournalJournal of Translational Medicine
Issue number1
Publication statusPublished - Jul 22 2019


  • Adjuvant
  • Anti-CTLA-4
  • Anti-PD-1
  • Biomarkers
  • BRAF inhibitor
  • Combination strategies
  • Immunotherapy
  • MEK inhibitor
  • Melanoma
  • Neoadjuvant
  • Target therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Perspectives in melanoma: Meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)'. Together they form a unique fingerprint.

Cite this